SUTRO BIOPHARMA INC (STRO)
Health Care · Oncology / ADC therapeutics · NASDAQ
Sutro Biopharma is a clinical-stage oncology firm using proprietary cell-free protein synthesis technology to develop specialized antibody-drug conjugates for cancer treatment.
What SUTRO BIOPHARMA INC does
Sutro Biopharma is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates (ADCs), bispecific ADCs, immunostimulatory ADCs, and dual-payload ADCs enabled by its proprietary XpressCF® and XpressCF+® cell-free protein synthesis platforms. The company's lead program is STRO-004, a single homogeneous ADC targeting tissue factor currently in Phase 1 trials for solid tumors, with preclinical assets STRO-006 (targeting integrin alpha v beta 6) and STRO-227 (a dual-payload ADC targeting PTK7). Sutro collaborates with leading pharma companies including Astellas, Merck, Celgene/BMS, and EMD Serono on multiple oncology programs.
Themes: antibody drug conjugates (ADCs), oncology / cancer therapeutics, cell-free protein synthesis, site-specific conjugation, bispecific therapeutics, immunostimulatory ADCs, novel protein engineering
Fundamentals
- Price$21.04 as of 2026-08-21 close
- Market cap$349M as of 2026-08-21
- 1-year return+147.5% 2025-08-21 close $8.50 → 2026-08-21 close $21.04
- P/En/a negative earnings
- Net margin-154.2% as of 2026-08-24
- ROE-223.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+49.9% as of 2026-08-24
- Revenue CAGR (3y)+14.8% SEC XBRL
- Beta1.47 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How STRO compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SUTRO BIOPHARMA INC looks technically
SUTRO BIOPHARMA INC (STRO) is trading 2.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 182 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It made a new 20-day low about 6 trading days ago. It is 52.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 2.6% below its 200-day average, the long-term trend line — a long-term downtrend | -2.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.35 | $26.35 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $21.60 | $21.60 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 18.37. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave downward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 182 trading days ago — a "golden cross", a bullish long-term signal | 182 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control | 30.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 37, neither overbought (above 70) nor oversold (below 30) | 36.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($18.37 to $26.35) — its "stochastic" reading is 33 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 33.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $43.85 | $43.85 |
|---|---|---|
| From the 52-week high | it is 52.0% below its 52-week high (its highest price of the past year) | -52.0% |
| Above the 52-week low | it is 194.3% above its 52-week low (its lowest price of the past year) | +194.3% |
| Below the 52-week high | it is 52.0% below its highest point of the past year | 52.0% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $283.00 (set on 2021-02-08) | $283.00 |
| Given back of the 52-week move | over the past year its closes ranged ($7.30 to $40.91), and it has given back a bit over half of its rise from last year’s low — 59% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.06 to $20.14. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 59.1% |
| From the all-time high | it is 92.6% below its all-time high | -92.6% |
| Nearest price level | it is trading 1.9% below a resistance level at $21.43 — a price it turned at three times since 2025-01-07, most recently on 2025-02-06. Since 2024-08-21 it has 5 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.9% |
| All-time low | its lowest closing price on record is $5.20 (set on 2025-04-17) | $5.20 |
| Above the all-time low | it is 304.6% above its all-time low | +304.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.01 between its high and its low — about 9.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.01 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.94 and $26.81 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.94 – $23.38 – $26.81 |
| Typical daily range (% of price) | its price moves about 9.6% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.6% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges below its 200-day average price (2.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.65× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.1% since the prior reading | -1.1% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 5.8% below the previous close 7 sessions ago and has not traded back through the level it left behind at 25.04 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -5.8% |
| Gap filled | a 2.7% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 4 sessions in a row, a -5.57% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 4 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.9 percentage points (the stock lost 8.5% while the market gained 2.3%) | -10.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 34.4 percentage points (the stock lost 31.3% while the market gained 3.1%) | -34.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 3.2 percentage points (the stock gained 14.2% while the market gained 11.1%) | +3.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 127.0 percentage points (the stock gained 147.5% while the market gained 20.5%) | +127.0% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, trading below its 200-day average, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 28% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 21.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -28.1% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 21% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $26.47 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | -20.5% |
|---|
Price levels it has turned at before
STRO last closed at $21.04 on 2026-08-21. Since 2024-08-21 it has turned at 5 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $21.43 | Resistance | 1.9% above the last close | turned there three times · 2025-01-07 to 2025-02-06 |
| $23.53 | Resistance | 11.8% above the last close | turned there twice · 2026-04-07 to 2026-06-03 |
| $18.05 | Support | 14.2% below the last close | turned there twice · 2024-12-31 to 2025-01-29 |
| $26.45 | Resistance | 25.7% above the last close | turned there twice · 2026-03-09 to 2026-08-05 |
| $13.10 | Support | 37.7% below the last close | turned there twice · 2025-04-24 to 2025-10-21 |
| $10.08 | Support | 52.1% below the last close | turned there three times · 2025-07-24 to 2026-01-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $18.37.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close above $22.26.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Analyst price target recently CUT · Most volatile (6%+ typical daily range) · Near the golden pocket (has given back about two thirds of its 52-week move) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.43 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$47.23 range $10.00 – $61.00; median $50.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for STRO
- Consensus EPS estimate-$2.29 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Company has a history of significant losses and may never achieve profitability; currently unprofitable with -154% net margin as of July 2026.","Substantial additional funding required to advance development of product candidates; risk of inability to secure adequate capital on reasonable terms to continue development and operations.","Lead product STRO-004 and other candidates are in early clinical/preclinical stages and may fail, face competitive pressures, or experience significant development delays that could materially harm commercial viability; Nasdaq listing compliance risk due to stock price not meeting minimum listing requirements."]
What changed in the latest 10-Q
AI-assisted comparison of STRO's 10-Q filed 2026-05-14 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-14) references Annual Report on Form 10-K for year ended December 31, 2025, whereas older filing (2025-11-06) references year ended December 31, 2024
- Newer filing describes STRO-004 as 'single homogeneous ADC' that 'we are developing' (clinical stage), versus older filing stating 'we intend to develop' (preclinical stage)
- Newer filing states STRO-004 IND received in October 2025 and Phase 1 trial initiated in November 2025
- Newer filing reports dose-escalation phase progress: dose level 2 cohort completed, dose level 3 cohort initiated in February 2026, with expectation to report initial preliminary data in mid-2026
- Newer filing specifies Phase 1 trial design details including patient populations (non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer)
- Newer filing states strong tolerability in non-human primates at up to 50 mg/kg
- Newer filing names STRO-227 explicitly as dual-payload ADC candidate targeting PTK7
- Newer filing states Astellas collaboration involves 'multitarget iADC collaboration with Astellas Pharma Inc.' and clinical trials initiated in first quarter of 2026
- Newer filing describes STRO-006 as having 'IND-enabling activities underway' with potential IND submission 'in connection with this program in 2026'
- Newer filing states PTK7-targeting dual-payload ADC IND submission anticipated in 'late 2026'
- Removed:
- Older filing (2025-11-06) describes company as 'an oncology company' versus newer filing states 'a clinical stage oncology company'
- Older filing describes STRO-004 and STRO-006 as 'most advanced preclinical stage programs' versus newer filing characterizes STRO-004 as clinical stage
- Older filing states STRO-004 'plan to initiate clinical development by the end of 2025' versus newer filing reports Phase 1 already initiated
- Older filing lists 'STRO-006, an ADC targeting Integrinβ6, or Iβ6' versus newer filing uses 'ITGβ6'
- Older filing describes preclinical portfolio as including 'multiple dual-payload ADCs, including iADCs' versus newer filing specifies STRO-227 as the first wholly-owned dual-payload ADC
- Older filing states PTK7-targeting dual-payload ADC IND anticipated in 2027 versus newer filing states 'late 2026'
- Older filing describes STRO-006 IND enabling activities 'in the second half of 2026' versus newer filing states 'in connection with this program in 2026' without specific timing
- Older filing states 'ongoing multitarget iADC collaboration with Astellas' without Pharma Inc. designation or clinical trial status
- Older filing includes final sentence about November 2023 Vaxcyte option exercise that is cut off in newer filing text provided
- Reworded:
- Older 'Iβ6' notation for Integrin target changed to 'ITGβ6' in newer filing
- Older 'filed an IND' changed to 'submitted an IND' in newer filing for STRO-004
- Older 'filing an IND' changed to 'submitting an IND' in newer filing for PTK7 program
- Older 'dual-payload ADCs, which include immunostimulatory ADCs, or iADCs' reordered to 'dual-payload ADCs, or dpADCs' and separated iADCs as distinct modality in newer filing
- Older 'our most advanced preclinical stage programs are STRO-004 and STRO-006, with STRO-004 being our current highest priority wholly-owned product candidate' changed to 'Our highest priority wholly-owned product candidate is STRO-004' in newer filing
- Older 'which we intend to develop' changed to 'which we are developing' for STRO-004 in newer filing
- Notes:
- The older filing text appears truncated at the end (cuts off mid-sentence regarding Vaxcyte), potentially affecting completeness of removal assessment for final paragraph
- Comparison is limited to the MD&A section provided; full document context not available
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for STRO — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding STRO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 526,013
- Reported value $13,102,985
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
STRO had 1,744,843 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
STRO had 10.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.35 days to cover at the same settlement.
- Reported short interest (shares) 1,744,843
- Short interest (% of shares outstanding) 10.5%
- Prior settlement (shares) 1,652,824
- Reported change 5.57%
- Days to cover (reported) 6.35
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Seagen Inc. (SGEN)
- Genmab A/S
- Immunocore
- Gritstone bio
- Alnylam Pharmaceuticals (ALNY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare STRO vs…
Frequently asked questions
What does SUTRO BIOPHARMA INC (STRO) do?
Sutro Biopharma is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates (ADCs), bispecific ADCs, immunostimulatory ADCs, and dual-payload ADCs enabled by its proprietary XpressCF® and XpressCF+® cell-free protein synthesis platforms. The company's lead program is STRO-004, a single homogeneous ADC targeting tissue factor currently in Phase 1 trials for solid tumors, with preclinical assets STRO-006 (targeting integrin alpha v beta 6) and STRO-227…
What sector is SUTRO BIOPHARMA INC (STRO) in?
SUTRO BIOPHARMA INC (STRO) is classified in the Health Care sector. Its industry is Oncology / ADC therapeutics. It trades on NASDAQ.
Who are SUTRO BIOPHARMA INC's (STRO) competitors?
Notable peers of SUTRO BIOPHARMA INC (STRO) include Seagen Inc., Genmab A/S, Immunocore, Gritstone bio and Alnylam Pharmaceuticals. This peer set is informational only — not financial advice.
Is SUTRO BIOPHARMA INC (STRO) overbought or oversold right now?
SUTRO BIOPHARMA INC (STRO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 37, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on STRO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.